Cervical cancer screening, within reach.
Cervixel develops CRISPR-based rapid diagnostic tests for cervical cancer, designed for accessibility and built around Europe's regulatory rigour. Our work is aligned with the WHO 2030 cervical cancer elimination goal.
Independent recognition for our work.
1st place — Hospiton Cancer Hackathon
Recognised for the early RapidCan concept against entries from clinical and engineering teams across Europe.
Invited to Cambridge University
Selected for an in-person research and translation programme at Cambridge to advance the diagnostic platform.
BSV Ventures Incubation
Shortlisted for BSV Ventures' #7 incubation programme — one of a small group of deep-tech startups selected from across Europe and the United States.
Partnership with Nacionalinis vėžio centras
Partnership with the National Cancer Center in Lithuania, supporting clinical translation and validation work.
RapidCan
A CRISPR-based rapid diagnostic test for cervical cancer. RapidCan is engineered to detect molecular signals associated with the disease without depending on a centralised laboratory workflow.
Preorder pricing is structured for healthcare providers, distributors, and institutional buyers at scale — the organisations that decide what reaches a clinic, a community programme, or a national screening initiative.
RapidCan is currently under CE marking review along the IVDR pathway. Clinical studies are active and ongoing. We will communicate verified performance characteristics as those studies are published.
Research and development partnerships
Beyond RapidCan, Cervixel works with biotech and pharmaceutical organisations on the molecular and regulatory work that decides whether a diagnostic ever reaches a patient.
- Service
CRISPR assay development
Design and optimisation of Cas-based detection assays for nucleic-acid targets in clinical and research settings.
- Service
Molecular diagnostics consulting
Strategic guidance on assay architecture, sample workflows, and translation from concept to clinical use.
- Service
Clinical validation support
Study design, partner sourcing, and analytical-to-clinical performance evaluation for diagnostic candidates.
- Service
Regulatory strategy
IVDR-aligned planning for CE marking pathways, technical-file structuring, and post-market surveillance.
- Service
Contract research
Targeted laboratory work for biotech and pharmaceutical partners — flexible scope, rigorous documentation.
- Service
Global procurement services
Sourcing of medical devices, IVDs, and pharmaceuticals from European supply chains for international partners, with full audit and compliance documentation.
Eliminating cervical cancer is a 2030 goal. We're building the tools to get there.
The World Health Organization has set a 2030 target for the elimination of cervical cancer as a public health problem. Achieving it requires screening that is accurate, accessible, and usable in places where centralised laboratory infrastructure does not exist.
Cervixel was founded in Vilnius to contribute to that goal — by designing molecular diagnostics that can travel further than the traditional pathology lab, and by building from Europe with the regulatory rigour the work demands.
“Molecular diagnostics has spent forty years tied to centralised laboratories. CRISPR is what finally changes that equation. At Cervixel, we’re designing for the clinic, the field, and eventually the home — because that’s where screening actually has to happen if we want to close the gap.”
John Muhammadi, M.D., MBA
Founder & CEO
Talk to the team
Whether you’re evaluating RapidCan or exploring a partnership, we’d like to hear from you.